Tag: Prescription Drugs
Company Seeks FDA Emergency Approval for COVID-19 Antibody Therapy
Request based on partial clinical trial findings suggesting the drug reduces symptoms in mild or moderate COVID-19
Abemaciclib Beneficial for HR+, HER2− Early Breast Cancer
Significant improvements seen in rates of invasive disease-free survival, distant recurrence-free survival
Hydroxychloroquine Not Beneficial for SARS-CoV-2 Preexposure Prophylaxis
No clinical benefit seen versus placebo for hospital-based health care workers exposed to patients with COVID-19
ASA: Sustained Decrease Seen in Prescription Opioid Abuse in U.S.
Significant declines seen from 2002 to 2013 and 2014 and from 2015 to 2016, 2017, 2018
Atezolizumab Prolongs Survival in NSCLC With PD-L1 Expression
Overall survival longer than for chemotherapy in metastatic NSCLC with high PD-L1 expression
Gabapentin Does Not Lower Pain Scores in Chronic Pelvic Pain
Treatment also linked to more serious adverse events
Hydroxychloroquine Tied to Heart Problems Prior to Pandemic
Adverse outcomes include cardiomyopathy, QT prolongation, cardiac arrhythmias, heart failure
FDA Requiring Labeling Changes to Benzodiazepine Prescribing Information
Update to Boxed Warning must include risks for abuse, misuse, addiction, physical dependence, withdrawal reaction
Guidelines Updated for Managing Dyslipidemia to Cut CVD Risk
Moderate-dose statin therapy recommended for patients with 10-year CVD risk ≥12 percent
Major Adverse CV Event Risk Reduced With SGLT2 Inhibitors
Risks for MACE, MI, cardiovascular death, heart failure, all-cause mortality lower versus DPP-4 inhibitors
